Cargando…
Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature
Radiotherapy can elicit abscopal effects in non-irradiated metastases, particularly under immune checkpoint blockade (ICB). We report on two elderly patients with oligometastatic melanoma treated with anti-PD-1 and stereotactic body radiation therapy (SBRT). Before treatment, patient 1 showed strong...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413872/ https://www.ncbi.nlm.nih.gov/pubmed/32350591 http://dx.doi.org/10.1007/s00262-020-02587-8 |
_version_ | 1783568880501784576 |
---|---|
author | Watanabe, Tsubasa Firat, Elke Scholber, Jutta Gaedicke, Simone Heinrich, Corinne Luo, Ren Ehrat, Nicolas Multhoff, Gabriele Schmitt-Graeff, Annette Grosu, Anca-Ligia Abdollahi, Amir Hassel, Jessica C. von Bubnoff, Dagmar Meiss, Frank Niedermann, Gabriele |
author_facet | Watanabe, Tsubasa Firat, Elke Scholber, Jutta Gaedicke, Simone Heinrich, Corinne Luo, Ren Ehrat, Nicolas Multhoff, Gabriele Schmitt-Graeff, Annette Grosu, Anca-Ligia Abdollahi, Amir Hassel, Jessica C. von Bubnoff, Dagmar Meiss, Frank Niedermann, Gabriele |
author_sort | Watanabe, Tsubasa |
collection | PubMed |
description | Radiotherapy can elicit abscopal effects in non-irradiated metastases, particularly under immune checkpoint blockade (ICB). We report on two elderly patients with oligometastatic melanoma treated with anti-PD-1 and stereotactic body radiation therapy (SBRT). Before treatment, patient 1 showed strong tumor infiltration with exhausted CD8+ T cells and high expression of T cell-attracting chemokines. This patient rapidly mounted a complete response, now ongoing for more than 4.5 years. Patient 2 exhibited low CD8+ T cell infiltration and high expression of immunosuppressive arginase. After the first SBRT, his non-irradiated metastases did not regress and new metastases occurred although neoepitope-specific and differentiation antigen-specific CD8+ T cells were detected in the blood. A second SBRT after 10 months on anti-PD-1 induced a radiologic complete response correlating with an increase in activated PD-1-expressing CD8 T cells. Apart from a new lung lesion, which was also irradiated, this deep abscopal response lasted for more than 2.5 years. However, thereafter, his disease progressed and the activated PD-1-expressing CD8 T cells dropped. Our data suggest that oligometastatic patients, where a large proportion of the tumor mass can be irradiated, are good candidates to improve ICB responses by RT, even in the case of an unfavorable pretreatment immune signature, after progression on anti-PD-1, and despite advanced age. Besides repeated irradiation, T cell epitope-based immunotherapies (e.g., vaccination) may prolong antitumor responses even in patients with unfavorable pretreatment immune signature. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00262-020-02587-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7413872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-74138722020-08-17 Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature Watanabe, Tsubasa Firat, Elke Scholber, Jutta Gaedicke, Simone Heinrich, Corinne Luo, Ren Ehrat, Nicolas Multhoff, Gabriele Schmitt-Graeff, Annette Grosu, Anca-Ligia Abdollahi, Amir Hassel, Jessica C. von Bubnoff, Dagmar Meiss, Frank Niedermann, Gabriele Cancer Immunol Immunother Original Article Radiotherapy can elicit abscopal effects in non-irradiated metastases, particularly under immune checkpoint blockade (ICB). We report on two elderly patients with oligometastatic melanoma treated with anti-PD-1 and stereotactic body radiation therapy (SBRT). Before treatment, patient 1 showed strong tumor infiltration with exhausted CD8+ T cells and high expression of T cell-attracting chemokines. This patient rapidly mounted a complete response, now ongoing for more than 4.5 years. Patient 2 exhibited low CD8+ T cell infiltration and high expression of immunosuppressive arginase. After the first SBRT, his non-irradiated metastases did not regress and new metastases occurred although neoepitope-specific and differentiation antigen-specific CD8+ T cells were detected in the blood. A second SBRT after 10 months on anti-PD-1 induced a radiologic complete response correlating with an increase in activated PD-1-expressing CD8 T cells. Apart from a new lung lesion, which was also irradiated, this deep abscopal response lasted for more than 2.5 years. However, thereafter, his disease progressed and the activated PD-1-expressing CD8 T cells dropped. Our data suggest that oligometastatic patients, where a large proportion of the tumor mass can be irradiated, are good candidates to improve ICB responses by RT, even in the case of an unfavorable pretreatment immune signature, after progression on anti-PD-1, and despite advanced age. Besides repeated irradiation, T cell epitope-based immunotherapies (e.g., vaccination) may prolong antitumor responses even in patients with unfavorable pretreatment immune signature. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00262-020-02587-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-04-29 2020 /pmc/articles/PMC7413872/ /pubmed/32350591 http://dx.doi.org/10.1007/s00262-020-02587-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article Watanabe, Tsubasa Firat, Elke Scholber, Jutta Gaedicke, Simone Heinrich, Corinne Luo, Ren Ehrat, Nicolas Multhoff, Gabriele Schmitt-Graeff, Annette Grosu, Anca-Ligia Abdollahi, Amir Hassel, Jessica C. von Bubnoff, Dagmar Meiss, Frank Niedermann, Gabriele Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature |
title | Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature |
title_full | Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature |
title_fullStr | Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature |
title_full_unstemmed | Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature |
title_short | Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature |
title_sort | deep abscopal response to radiotherapy and anti-pd-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413872/ https://www.ncbi.nlm.nih.gov/pubmed/32350591 http://dx.doi.org/10.1007/s00262-020-02587-8 |
work_keys_str_mv | AT watanabetsubasa deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT firatelke deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT scholberjutta deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT gaedickesimone deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT heinrichcorinne deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT luoren deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT ehratnicolas deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT multhoffgabriele deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT schmittgraeffannette deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT grosuancaligia deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT abdollahiamir deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT hasseljessicac deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT vonbubnoffdagmar deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT meissfrank deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature AT niedermanngabriele deepabscopalresponsetoradiotherapyandantipd1inanoligometastaticmelanomapatientwithunfavorablepretreatmentimmunesignature |